Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Non Muscle Invasive Bladder Cancer (NMIBC) - Pipeline Review, H2 2016 - Key Vendors are Astellas Pharma, Celgene Corporation & Cold Genesys - Research and Markets

Research and Markets
Posted on: 27 Oct 16

Research and Markets has announced the addition of the "Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Mentioned:

  • Altor BioScience Corporation
  • APIM Therapeutics AS
  • Astellas Pharma Inc.
  • Bavarian Nordic A/S
  • BioCancell Ltd
  • Celgene Corporation
  • Cold Genesys, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Heat Biologics, Inc.
  • Merck & Co., Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Taris Biomedical LLC
  • UroGen Pharmaceuticals, Ltd.
  • Vakzine Projekt Management GmbH
  • Vaxiion Therapeutics, Inc.
  • Viralytics Ltd.
  • Viventia Bio Inc.

Key Topics Covered:

  1. Introduction
  2. Non Muscle Invasive Bladder Cancer (NMIBC) Overview
  3. Therapeutics Development
  4. Pipeline Products for Non Muscle Invasive Bladder Cancer (NMIBC) - Overview
  5. Pipeline Products for Non Muscle Invasive Bladder Cancer (NMIBC) - Comparative Analysis
  6. Non Muscle Invasive Bladder Cancer (NMIBC) - Therapeutics under Development by Companies
  7. Non Muscle Invasive Bladder Cancer (NMIBC) - Therapeutics under Investigation by Universities/Institutes
  8. Non Muscle Invasive Bladder Cancer (NMIBC) - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Non Muscle Invasive Bladder Cancer (NMIBC) - Products under Development by Companies
  13. Non Muscle Invasive Bladder Cancer (NMIBC) - Products under Investigation by Universities/Institutes
  14. Non Muscle Invasive Bladder Cancer (NMIBC) - Companies Involved in Therapeutics Development

For more information about this report visit http://www.researchandmarkets.com/research/2csjfr/non_muscle

View source version on businesswire.com: http://www.businesswire.com/news/home/20161027005699/en/

Business Wire
www.businesswire.com

Last updated on: 27/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.